by George Ciuciureanu | Jun 5, 2025 | Health, News
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker. The blog post explores how biomarkers improve diagnosis and personalized care in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Vancouver, Canada – June 5,...
by George Ciuciureanu | Jun 4, 2025 | Events, Health
Augurex to present a poster and share a second accepted abstract at EULAR 2025, taking place June 11–14 in Barcelona. New findings highlight the value of 14-3-3eta autoantibodies in improving early detection of axSpA, including in HLA-B27–negative patients. Vancouver,...
by George Ciuciureanu | Apr 30, 2025 | Events, Health
Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada. Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA). Vancouver, Canada...
by George Ciuciureanu | Apr 25, 2025 | Events, Health
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK Highlighting biomarker-based diagnostic innovations for RA and axSpA Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for...
by George Ciuciureanu | Apr 24, 2025 | Events, Health
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
by George Ciuciureanu | Apr 22, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing...
